400 related articles for article (PubMed ID: 36374768)
1. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
Guarneri V; Bras-Maristany F; Dieci MV; Griguolo G; Par L; Mar Ín-Aguilera M; Miglietta F; Bottosso M; Giorgi CA; Blasco P; Castillo O; Galv N P; Vivancos A; Villagrasa P; Parker JS; Perou CM; Conte P; Prat A
EBioMedicine; 2022 Nov; 85():104320. PubMed ID: 36374768
[TBL] [Abstract][Full Text] [Related]
2. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
Waks AG; Ogayo ER; Paré L; Marín-Aguilera M; Brasó-Maristany F; Galván P; Castillo O; Martínez-Sáez O; Vivancos A; Villagrasa P; Villacampa G; Tarantino P; Desai N; Guerriero J; Metzger O; Tung NM; Krop IE; Parker JS; Perou CM; Prat A; Winer EP; Tolaney SM; Mittendorf EA
JAMA Oncol; 2023 Jun; 9(6):835-840. PubMed ID: 37103927
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
Prat A; Guarneri V; Pascual T; Brasó-Maristany F; Sanfeliu E; Paré L; Schettini F; Martínez D; Jares P; Griguolo G; Dieci MV; Cortés J; Llombart-Cussac A; Conte B; Marín-Aguilera M; Chic N; Puig-Butillé JA; Martínez A; Galván P; Tsai YH; González-Farré B; Mira A; Vivancos A; Villagrasa P; Parker JS; Conte P; Perou CM
EBioMedicine; 2022 Jan; 75():103801. PubMed ID: 34990895
[TBL] [Abstract][Full Text] [Related]
5. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
6. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
Bueno-Muiño C; Echavarría I; López-Tarruella S; Roche-Molina M; Del Monte-Millán M; Massarrah T; Jerez Y; Ayala de la Peña F; García-Sáenz JÁ; Moreno F; Rodríguez-Lescure Á; Malón-Giménez D; Ballesteros García AI; Marín-Aguilera M; Galván P; Brasó-Maristany F; Waks AG; Tolaney SM; Mittendorf EA; Vivancos A; Villagrasa P; Parker JS; Perou CM; Paré L; Villacampa G; Prat A; Martín M
JAMA Oncol; 2023 Jun; 9(6):841-846. PubMed ID: 37103916
[TBL] [Abstract][Full Text] [Related]
7. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
Villacampa G; Tung NM; Pernas S; Paré L; Bueno-Muiño C; Echavarría I; López-Tarruella S; Roche-Molina M; Del Monte-Millán M; Marín-Aguilera M; Brasó-Maristany F; Waks AG; Pascual T; Martínez-Sáez O; Vivancos A; Conte PF; Guarneri V; Vittoria Dieci M; Griguolo G; Cortés J; Llombart-Cussac A; Muñoz M; Vidal M; Adamo B; Wolff AC; DeMichele A; Villagrasa P; Parker JS; Perou CM; Fernandez-Martinez A; Carey LA; Mittendorf EA; Martín M; Prat A; Tolaney SM
Ann Oncol; 2023 Sep; 34(9):783-795. PubMed ID: 37302750
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy de-escalation using an
Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
10. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
Gluz O; Nitz UA; Christgen M; Kuemmel S; Holtschmidt J; Schumacher J; Hartkopf A; Potenberg J; Lüedtke-Heckenkamp K; Just M; Schem C; von Schumann R; Kolberg-Liedtke C; Eulenburg CZ; Schinköthe T; Graeser M; Wuerstlein R; Kates RE; Kreipe HH; Harbeck N
JAMA Oncol; 2023 Jul; 9(7):946-954. PubMed ID: 37166817
[TBL] [Abstract][Full Text] [Related]
12. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
13. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A; Wang T; Cortés J; Rexer B; Paré L; Forero A; Wolff AC; Morales S; Adamo B; Brasó-Maristany F; Vidal M; Veeraraghavan J; Krop I; Galván P; Pavlick AC; Bermejo B; Izquierdo M; Rodrik-Outmezguine V; Reis-Filho JS; Hilsenbeck SG; Oliveira M; Dieci MV; Griguolo G; Fasani R; Nuciforo P; Parker JS; Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF
J Natl Cancer Inst; 2020 Jan; 112(1):46-54. PubMed ID: 31037288
[TBL] [Abstract][Full Text] [Related]
14. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
15. Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial.
Ahn HK; Sim SH; Suh KJ; Kim MH; Jeong JH; Kim JY; Lee DW; Ahn JH; Chae H; Lee KH; Kim JH; Lee KS; Sohn JH; Choi YL; Im SA; Jung KH; Park YH
JAMA Oncol; 2022 Sep; 8(9):1271-1277. PubMed ID: 35797012
[TBL] [Abstract][Full Text] [Related]
16. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
de Haas SL; Slamon DJ; Martin M; Press MF; Lewis GD; Lambertini C; Prat A; Lopez-Valverde V; Boulet T; Hurvitz SA
Breast Cancer Res; 2023 Jan; 25(1):2. PubMed ID: 36631725
[TBL] [Abstract][Full Text] [Related]
17. BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
Liefaard MC; van der Voort A; van Ramshorst MS; Sanders J; Vonk S; Horlings HM; Siesling S; de Munck L; van Leeuwen AE; Kleijn M; Mittempergher L; Kuilman MM; Glas AM; Wesseling J; Lips EH; Sonke GS
Breast Cancer Res; 2023 Jun; 25(1):71. PubMed ID: 37337299
[TBL] [Abstract][Full Text] [Related]
18. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
Brasó-Maristany F; Griguolo G; Chic N; Pascual T; Paré L; Maues J; Galván P; Dieci MV; Miglietta F; Giarratano T; Martínez-Sáez O; Marín-Aguilera M; Schettini F; Conte B; Angelats L; Vidal M; Adamo B; Muñoz M; Sanfeliu E; González B; Vivancos A; Villagrasa P; Parker JS; Perou CM; Conte P; Prat A; Guarneri V
J Natl Cancer Inst; 2023 Mar; 115(3):332-336. PubMed ID: 36576009
[TBL] [Abstract][Full Text] [Related]
19. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A; Rediti M; Tang G; Pascual T; Hoadley KA; Venet D; Rashid NU; Spears PA; Islam MN; El-Abed S; Bliss J; Lambertini M; Di Cosimo S; Huobe J; Goerlitz D; Hu R; Lucas PC; Swain SM; Sotiriou C; Perou CM; Carey LA
JAMA Oncol; 2024 May; 10(5):603-611. PubMed ID: 38546612
[TBL] [Abstract][Full Text] [Related]
20. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
Nitz UA; Gluz O; Christgen M; Grischke EM; Augustin D; Kuemmel S; Braun M; Potenberg J; Kohls A; Krauss K; Stefek A; Schumacher C; Forstbauer H; Reimer T; Fischer H; Liedtke C; Wuerstlein R; Schumacher J; Kates R; Kreipe H; Harbeck N
Ann Oncol; 2017 Nov; 28(11):2768-2772. PubMed ID: 28945833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
